- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 03.12.25 | Capricor's phase 3 win sets up 2nd approval attempt for Duchenne cell therapy | ||
| 03.12.25 | Pfizer-backed Triana scores $120M series B to take molecular glue degrader into clinic | ||
| 03.12.25 | Pharvaris clocks a pivotal win in race for rapid HAE relief, teeing up filing to challenge KalVista | ||
| 03.12.25 | Théa pens $280M deal for Iolyx's phase 3-ready dry eye disease drug | ||
| 03.12.25 | Muvon flexes muscle cell therapy data to challenge synthetic incontinence implants | ||
| 02.12.25 | CDER head Richard Pazdur set to retire shortly after appointment: Stat | ||
| 02.12.25 | FDA issues draft guidance to reduce primate testing for certain antibodies | ||
| 02.12.25 | Janux T-cell engager data sink stock, but analysts still see best-in-class potential | ||
| 02.12.25 | Tiziana to spin out IL-6 drug into new company, citing Big Pharma's interest in modality | ||
| 02.12.25 | Imvax takes brain cancer cell therapy to FDA, betting survival hit will overshadow primary miss | ||
| 01.12.25 | European Union teams up with Angelini to funnel €150M to European health startups | ||
| 01.12.25 | Regeneron makes $150M bet on Tessera's rare disease gene writing prospect | ||
| 01.12.25 | Akebia to pay $12M to Q32 Bio for centerpiece of rare kidney disease pipeline | ||
| 01.12.25 | Belite brings FDA filing into view with phase 3 Stargardt disease victory | ||
| 26.11.25 | Vaccine-focused Valneva consolidates R&D footprint by shuttering site, eliminating 30 roles | ||
| 26.11.25 | AI may be the key to reigniting VC interest in biotech: PitchBook | ||
| 26.11.25 | FDA delays decision on Ascendis' dwarfism prospect by 3 months | ||
| 25.11.25 | US commission recommends federal research revamp to avoid losing global biotech edge | ||
| 25.11.25 | AbbVie launches lab space award program for Quebec biotechs | ||
| 25.11.25 | Novo Nordisk expands pivotal amycretin program after dual agonist shines in diabetes | ||
| 24.11.25 | Sarepta shares positive safety update on DM1 asset as Arrowhead snares $200M milestone | ||
| 24.11.25 | Gilead hatches $400M biobucks deal for Swedish biotech's TREX1 cancer program | ||
| 24.11.25 | Versant's Dayra dawns with $50M Biogen pact, oral macrocyclic peptide mission | ||
| 24.11.25 | J&J's $5B Alzheimer's hope fades as anti-tau antibody posdinemab flops in phase 2 | ||
| 24.11.25 | Bayer's asundexian cuts stroke risk in phase 3, reviving hopes for FXIa class |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.